Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 145,313 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorder Clear all

Conditions: Covid19, Physical Disability
Interventions: heat therapy, exercise training; Behavioral
Lead sponsor: University of Massachusetts, Amherst; Other
Eligibility: 55 Years to 85 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Amherst, Massachusetts

Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions: Evolocumab Pre-filled Syringe, Evolocumab AI/pen; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 21
States / cities: Encino, California • Thousand Oaks, California • Ventura, California + 17 more

Conditions: Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer
Interventions: LDK378, AUY922; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more

Conditions: Prostatic Neoplasms
Interventions: VELCADE TM (bortezomib) for Injection; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Cleveland, Ohio + 1 more

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: Baptist Memorial Health Care Corporation; Other
Eligibility: Not listed
Enrollment: 781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Atrial Fibrillation
Interventions: HBI-3000, Placebo; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Naples, Florida • Springfield, Illinois • Tupelo, Mississippi + 1 more

Conditions: Cancer
Interventions: Oral lapatinib tablets or placebo tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 20
States / cities: Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more

Conditions: Autism Spectrum Disorders
Interventions: Intranasal Oxytocin (Trade name: Syntocinon); Drug
Lead sponsor: Robert Schultz; Other
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Any Disease or Condition, Healthy
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Celiac Disease
Interventions: Latiglutenase, Placebo; Drug · Other
Lead sponsor: Immunogenics, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Autism Spectrum Disorder, Implementation Science, Mental Health, Behavioral Health
Interventions: ATTAIN NAV Technology-Enhanced Family Navigation Model; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 4 Years to 16 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypertriglyceridemia
Interventions: REGN1500, placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,345,817 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Premature Birth, Obstetric Labor, Premature
Interventions: Family Nurture Intervention (FNI), Standard Care; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 26 Weeks to 34 Weeks
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Ridgewood, New Jersey • New York, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Bevacizumab, Carboplatin, Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 61
States / cities: Chandler, Arizona • Flagstaff, Arizona • Bellflower, California + 55 more

Conditions: Anal Cancer
Interventions: cetuximab, cisplatin, fluorouracil, radiation therapy; Biological · Drug · Radiation
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Boston, Massachusetts + 4 more

Conditions: Parkinson Disease, Other Neurological Disorders, Healthy
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Overweight and Obesity, Time Restricted Feeding, Alzheimer Disease
Interventions: Time Restricted Eating intervention, Successful Aging Comparison Group (LEARN); Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 65 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: 50 mg Usnoflast, 75 mg Usnoflast, Placebo; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: La Jolla, California • Orange, California • San Francisco, California + 12 more

Conditions: Uveal Melanoma, Ocular Melanoma
Interventions: Pembrolizumab, Olaparib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: sunitinib, capecitabine, WBRT; Drug · Radiation
Lead sponsor: Baylor Breast Care Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Covid19
Interventions: Water (E) Mouth rinse with the solution provided, Chlorhexidine gluconate (A) Mouth rinse with the solution provided, Hydrogen peroxide (B) Mouth rinse with the solution provided, Betadine (C) Mouth rinse with the solution provided, Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided; Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Augusta, Georgia

Conditions: Hypoventilation
Interventions: Placebo, Ketamine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: MGD-Meibomian Gland Dysfunction
Interventions: Thermal Vectored Pulsation; Device
Lead sponsor: Dunes Eye Consultants; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dakota Dunes, South Dakota

Search by objective public record fields.

Physical Rehabilitation of COVID-19 Survivors by Heat Therapy

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology

A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

Intranasal Oxytocin and Learning in Autism

UCSF Research Participant Registry

Latiglutenase as a Treatment for Celiac Disease

Refining and Implementing Technology-Enhanced Family Navigation to Promote Early Access and Engagement With Mental Health Services for Youth With Autism

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Breast Cancer Surveillance Consortium

Family Nurture Intervention in the NICU at The Valley Hospital

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer

Prevalence of Visual Dysfunction in Neurological Disorders

Fasting ENHANCE Pilot Study

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Brain Mets - Capecitabine Plus Sunitinib and WBRT

[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse

Ketamine Infusion and Hypoventilation

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED